An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Rate (PFR)
Week 16
No
Justin Ricker, MD
Study Director
AbbVie
United States: Food and Drug Administration
M06-880
NCT00517790
August 2007
June 2012
Name | Location |
---|---|
Site Reference ID/Investigator# 7194 | Fountain Valley, California 92708 |
Site Reference ID/Investigator# 5617 | Los Angeles, California 90033 |
Site Reference ID/Investigator# 7934 | Sacramento, California 95817 |
Site Reference ID/Investigator# 5646 | Aurora, Colorado 80045-0510 |
Site Reference ID/Investigator# 6627 | Waterbury, Connecticut 06708 |
Site Reference ID/Investigator# 7868 | Newark, Delaware 19718 |
Site Reference ID/Investigator# 7616 | Port St. Lucie, Florida 34952 |
Site Reference ID/Investigator# 5648 | Chicago, Illinois 60637 |
Site Reference ID/Investigator# 6739 | Evanston, Illinois 60201 |
Site Reference ID/Investigator# 8100 | Harvey, Illinois 60426 |
Site Reference ID/Investigator# 5269 | Indianapolis, Indiana 46202 |
Site Reference ID/Investigator# 6042 | St. Louis, Missouri 63110 |
Site Reference ID/Investigator# 6680 | East Orange, New Jersey 07018 |
Site Reference ID/Investigator# 5603 | Voorhees, New Jersey 08043 |
Site Reference ID/Investigator# 5652 | Buffalo, New York 14263 |
Site Reference ID/Investigator# 6184 | Charlotte, North Carolina 28211 |
Site Reference ID/Investigator# 6777 | Greensboro, North Carolina 27403 |
Site Reference ID/Investigator# 5650 | Memphis, Tennessee 38120 |